Mild Cognitive Impairment: Diagnosis and Subtypes

Nicholas I Bradfield1,2

  • 15396St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.

Insights

Mild cognitive impairment (MCI) is diagnosed using cognitive assessments and impacts daily living. Understanding MCI subtypes aids in predicting dementia risk and identifying individuals for potential treatments.

Area of Science:

  • Neurology
  • Gerontology
  • Psychiatry

Background:

  • Mild cognitive impairment (MCI) is a clinical diagnosis.
  • It involves subjective cognitive decline and objective impairment with preserved daily function.
  • MCI diagnosis is established through clinical interviews, informant history, and psychometric testing.

Purpose of the Study:

  • To review diagnostic criteria for MCI across various neurodegenerative conditions.
  • To highlight variations in criteria for subjective decline, cognitive impairment, and functional abilities.
  • To outline the classification of MCI into subtypes and discuss its clinical utility.

Main Methods:

  • Review of consensus group criteria for MCI in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and vascular cognitive impairment.
  • Analysis of differences in criteria for subjective cognitive decline, objective impairment thresholds, and functional descriptions.
  • Examination of MCI subtypes based on cognitive impairment patterns.

Main Results:

  • Diagnostic criteria for MCI exhibit subtle but significant differences among consensus groups.
  • Variations exist in defining subjective decline, objective impairment, and functional preservation.
  • MCI can be classified into four subtypes based on memory and domain impairment patterns.

Conclusions:

  • Standardizing MCI diagnostic criteria is crucial for consistent clinical application.
  • Understanding MCI subtypes aids in predicting progression to dementia.
  • MCI serves as a critical nosology for studying neurodegenerative disease progression and identifying treatment candidates.

Related Concept Videos

Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
245
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
763
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
215
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
241
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
390
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
302